Background {#Sec1}
==========

Current guidelines suggest low-risk pulmonary embolism (PE) patients are candidates for treatment at home or with an abbreviated hospital stay versus \~5+ days of in-hospital management \[[@CR1]\]. Prior studies suggest up to 50% of PE patients may be treated in such a fashion \[[@CR2]\].

In the United States (US), observation stays are intended to manage patients for short periods to determine appropriateness for inpatient admission, with the determination of admission/discharge occurring within 2-midnights. Observation stays may serve as an alternative to inpatient management for low-risk PE patients. Reimbursement policy changes have led to an increasing use of observation stays \[[@CR3]--[@CR6]\]. We assessed agreement between observation management of PE and claims-based and clinical risk stratification criteria using administrative claims data.

Methods {#Sec2}
=======

We performed a retrospective analysis using Premier claims data from 11/2012 to 3/2015. Premier captures \~20% of all discharges from US acute care hospitals. This study was performed in accordance with the Declaration of Helsinki. All data included in the Premier Perspective Comparative Hospital Database are de-identified and are in compliance with the Health Insurance Portability and Accountability Act (HIPAA) of 1996 to preserve participant anonymity and confidentiality. For this reason, this study was exempt from institutional review board oversight and did not require an approval by an ethics committee. The data used in this study was under license from Premier Inc. and provided through the study sponsor, Janssen Scientific Affairs, LLC.

To be included, adult patients had to have undergone an observation stay (self-reported by hospitals) with an International Classification of Diseases, 9^th^-revision (ICD-9) diagnosis code for PE (415.1x) in the primary position, have a claim for ≥1 diagnostic test for PE on day 0--2 (computed tomography, ventilation-perfusion scan, pulmonary angiography) and received pharmacologic (anticoagulation, thrombolysis) and/or non-pharmacologic (pulmonary embolectomy, filter placement) PE treatment \[[@CR1]\].

Patient risk for early post-PE mortality was assessed using the validated In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) equation \[1/(1 + exp(−x)); x = −5.833 + (0.026 × age) + (0.402 × myocardial infarction) + (0.368 × chronic lung disease) + (0.464 × stroke) + (0.638 × prior major bleeding) + (0.298 × atrial fibrillation) + (1.061 × cognitive impairment) + (0.554 × heart failure) + (0.364 × renal failure) + (0.484 × liver disease) + (0.523 × coagulopathy) + (1.068 × cancer)\], with an estimated in-hospital mortality risk \>1.5% deemed higher-risk \[[@CR7]--[@CR9]\]. We also determined the proportion of patients with characteristics placing them at higher-risk for early mortality or other complications included in the simplified PE severity index (sPESI) or Hestia criteria (age \> 80 years, heart failure, chronic lung disease, renal impairment, liver disease, high-risk for major bleeding, cancer or a need for early thrombolysis/embolectomy \[proxy for hemodynamic instability\]) when assessable in the claims database \[[@CR10], [@CR11]\].

IMPACT mortality risk and patient characteristics were summarized using descriptive statistics. Percentages and means ± standard deviations or medians (25%, 75% range) were used to summarize categorical and continuous data. Statistical analysis was performed in IBM SPSS v22 (IBM Corp., Armonk, NY, USA).

Results {#Sec3}
=======

In total, 47,607 hospital encounters for PE were identified and 3.4% were coded as observation stays. Using IMPACT, \~46% of observation stay patients were at higher-risk for early post-PE mortality (Table [1](#Tab1){ref-type="table"}). Over one-third of PE patients managed via an observation stay had ≥1 criteria placing them at high-risk for early mortality. The proportion of patients with co-morbid heart failure, renal or liver disease, high-risk for major bleeding, cancer and requiring thrombolysis/pulmonary embolectomy were low (\<4.5% for each), but 7.8% patients were \>80 years-of-age and 19.4% had chronic lung disease. One patient died during hospitalization (out-of-hospital mortality is not available in Premier) and 28% stayed \>2-midnights. High-risk patients by IMPACT or those with ≥1 high-risk criteria had longer length-of-stay (*p* ≤ 0.005 for both using a generalized linear model with a gamma distribution and log-link).Table 1Characteristics of pulmonary embolism patients managed through observation staysCharacteristicIMPACT low-risk patients, n (%)\
*N* = 876IMPACT higher-risk patients, n (%)\
*N* = 757No high-risk criteria patients, n (%) *N* = 1,090≥1 High-risk criteria patients, n (%)\
*N* = 543Age (mean ± SD)43.7 ± 12.370.1 ± 10.752.3 ± 15.863.4 ± 18.5Male gender385 (43.9)340 (44.9)503 (46.1)222 (40.9)High-risk criteria included in sPESI or Hestia criteria Age \>80 years0 (0)127 (16.8)0 (0)127 (23.4) Heart failure4 (0.5)68 (9.0)0 (0)72 (13.3) Chronic lung disease91 (10.4)226 (29.9)0 (0)317 (58.4) Renal impairment3 (0.3)67 (8.9)0 (0)70 (12.9) Severe liver disease6 (0.7)23 (3.0)0 (0)29 (5.3) High risk for major bleeding^a^1 (0.1)9 (1.2)0 (0)10 (1.8) Cancer0 (0)46 (6.1)0 (0)46 (8.5) Required thrombolysis or embolectomy (days 0--2)2 (0.2)2 (0.3)0 (0)4 (0.7)Estimated IMPACT^b^ mortality risk, % (mean ± SD)1.0 ± 0.33.2 ± 2.51.3 ± 0.73.4 ± 2.9 Myocardial infarction1 (0.1)0 (0)0 (0)1 (0.2) Stroke0 (0)2 (0.3)0 (0)2 (0.4) Atrial Fibrillation3 (0.3)85 (11.2)31 (2.8)57 (10.5) Cognitive impairment0 (0)57 (7.5)14 (1.3)43 (7.9) Coagulopathy1 (0.1)35 (4.6)18 (1.7)18 (3.3)Length of stay, days (mean ± SD)\
(median \[25%, 75% range\])2.1 ± 0.8\
2.0 (2.0, 3.0)2.4 ± 1.6\
2.0 (2.0, 3.0)2.2 ± 1.3\
2.0 (2.0, 3.0)2.3 ± 1.0\
2.0 (2.0, 3.0)*IMPACT* In-hospital Mortality for PulmonAry embolism using Claims daTa, *SD* standard deviation, *sPESI* simplified pulmonary embolism severity index^a^Active or recent history of major bleed^b^The multivariable IMPACT equation is: 1/(1 + exp(−x); where x = −5.833 + (0.026\*age) + (0.402\*myocardial infarction) + (0.368\*chronic lung disease) + (0.464\*stroke) + (0.638\*prior major bleeding) + (0.298\*atrial fibrillation) + (1.061\*cognitive impairment) + (0.554\*heart failure) + (0.364\*renal failure) + (0.484\*liver disease) + (0.523\*coagulopathy) + (1.068\*cancer)

Discussion {#Sec4}
==========

Our study suggest anywhere from one-third to about half of PE patients managed via an observation stay in the US would be classified as higher-risk for early post-PE mortality according to claims-based or clinical risk stratification criteria \[[@CR7]--[@CR11]\]. Advanced age and chronic lung disease were the most frequent "high-risk" characteristics identified in observation stay-managed patients.

The substantial proportion of observation stay patients in our study classified at higher-risk by IMPACT and select components of the sPESI and the Hestia criteria highlights the lack of agreement between US observation management of PE and risk stratification tools. Whether this observed disagreement suggests inappropriate use of observation stays is unknown. It does suggest; however, that risk stratification tools may be used infrequently by practitioners in routine practice \[[@CR12]--[@CR14]\]. Studies have reported common clinician barriers to using risk stratification tools including difficulties in implementation in routine practice \[[@CR12], [@CR13]\], lack of training in their use, regulatory constraints and the nature of the physician-patient relationship \[[@CR14]\]. Also of concern, risk stratification tools tend to oversimplify risk assessment (accurately identifying those at very low-risk, but classify a large majority who inevitably do not experience a complication as higher-risk) \[[@CR12]\]. This overall lack of prognostic accuracy likely explains some inconsistencies between tool recommendations and clinical gestalt.

Whether clinical gestalt alone is optimal for identifying PE patients suitable for abbreviated stays is unclear. In a meta-analysis by Piran et al. \[[@CR15]\], the pooled risk of recurrent venous thromboembolism in outpatient-treated PE patients was shown not to differ between clinical gestalt and risk stratification methods (1.9% vs. 1.4%). Of note, nearly all studies examined in this meta-analysis were conducted in non-US centers decreasing its generalizability to US practice. Future studies to determine the prognostic accuracy of clinical gestalt in comparison to accepted risk stratification tools are needed.

Our study has limitations worth noting. First, Premier does not provide access to clinical data including vital signs (e.g., blood pressure, heart or respiratory rate, oxygen saturation), out-of-hospital mortality or clot burden. Thus, we could not apply commonly used clinical criteria, tools such as PESI or assess all criteria included in the sPESI and Hestia tools. Inclusion of these data could have only increased the percentage of patients classified as higher-risk, and as a result, we likely underestimated the percentage of patients at high-risk of early post-PE mortality. However, nearly half of observation stay patients in our analysis were identified as high-risk according to the IMPACT equation, which was specifically designed for identification of low-risk PE patients using claims data and shown to have similar prognostic accuracy for both in-hospital and 30-day mortality as PESI, sPESI and Hestia \[[@CR7]--[@CR9]\]. Second, we did not have 30-day mortality data available and therefore cannot comment on whether these observation stay and higher-risk patients had subsequent adverse outcomes after discharge. Finally, since the overall proportion of patients being managed through observations stays in the US is limited, it is possible that other unidentified factors (e.g., societal or economic) are influencing the generalizability of these findings.

Conclusion {#Sec5}
==========

Our analysis suggests patient selection for abbreviated stays is not consistent with claims-based risk stratification tools and accepted clinical criteria denoting higher-risk for early mortality.
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